LOGAN THRASHER: Open Payments
NPI 1821560384 · HOOVER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,781 in 175 payments from 17 companies in 2025. Trend: 2023 $5,569 · 2024 $4,605 · 2025 $4,781
Food & beverage: $4,774Education: $8
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $861 |
| Janssen Pharmaceuticals, Inc | 27 | $787 |
| Axsome Therapeutics, Inc. | 19 | $673 |
| Vanda Pharmaceuticals Inc. | 14 | $478 |
| Neurocrine BioSciences, Inc. | 13 | $437 |
| ABBVIE INC. | 23 | $366 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $313 |
| Lundbeck LLC | 8 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $191 |
| Supernus Pharmaceuticals, Inc. | 11 | $136 |
Products named: REXULTI, Auvelity, INVEGA SUSTENNA, FANAPT, INGREZZA, VRAYLAR, CAPLYTA, SPRAVATO.
Industry payments across AL — which companies pay providers there.
